With over 32 000 new stroke cases reported in recent years, the Gauteng Department of Health urges residents to learn the ...
It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.
The results have potential to change clinical practice.NEW ORLEANS — Left atrial appendage closure in patients with atrial ...
OCEAN was an open-label trial conducted in Australia, Belgium, Canada, China, Germany, and Israel. Eligible participants had ...
OCEAN, said Albert, provides important risk-benefit data that doctors can now use in discussions with their patients. For ...
23hon MSN
This is the world’s first entire arm exoskeleton, giving stroke patients more ‘independence'
One in four people suffers a stroke during their lifetime, according to the World Stroke Organisation. Stroke survivors with ...
In patients with atherosclerosis and/or diabetes without a prior heart attack or stroke, evolocumab cut the risk for first ...
A new trial co-led by the Ottawa Heart Institute and the Research Institute of the McGill University Health Centre shows that ...
For some people with high cholesterol, making lifestyle changes and taking routine cholesterol-lowering statin medications ...
The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease ...
The Canadian Press on MSN
Blood thinners no longer needed for many with irregular heatbeats, study suggests
Those who have undergone successful corrective procedures for irregular heart beats may no longer need to commit to long-term ...
Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback